Yazarlar : Jabbour E, Thomas D, Kantarjian H, Zhou L, Pierce S, Cortes J, Verstovsek S.

Yayın : Blood

Yayın Yılı : 2011

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/21622644?dopt=Abstract

Konu : Lösemi

Literatür İçeriği :  

Abstract

Using the IWG-MRT consensus criteria, we re-assessed the efficacy of thalidomide and lenalidomide in 125 patients with myelofibrosis treated in 3 consecutive phase II trials: 44 received single-agent thalidomide; 41 single-agent lenalidomide; and 40 a combination of lenalidomide+prednisone. Thalidomide group included significantly more untreated patients and patients with performance status of 2. Lenalidomide-based therapy produced higher efficacy (34-38%) than thalidomide (16%; p=0.06). Responses to thalidomide were seen within 3-15 weeks, while responses to lenalidomide-based therapy were also seen after prolonged course of therapy (range 2-45 weeks). Lenalidomide+prednisone therapy resulted in significantly longer response duration (median 34 months) than single-agent lenalidomide or thalidomide (median 7 and 13 months, respectively; p=0.042). Fewer patients (p=0.001) discontinued lenalidomide+prednisone therapy (13%) due to side effects then patients on single-agents therapy (32-39%). In conclusion, the combination of lenalidomide+prednisone appears to be more effective and safer than single-agent thalidomide or lenalidomide.

Literatür Arşivi